<DOC>
	<DOCNO>NCT00509847</DOCNO>
	<brief_summary>The purpose study establish tolerability treatment human lactoferrin 1-11 peptide ( hLF1-11 ) administer intravenously single dose give 10 consecutive day , patient bacteremia due staphylococcus epidermidis .</brief_summary>
	<brief_title>A Study Tolerability Early Efficacy hLF1-11 Patients With Bacteremia Due S. Epidermidis</brief_title>
	<detailed_description>RATIONALE FOR THE STUDY Choice Drug Staphylococcus epidermidis relatively uncommon find blood culture , case find patient intravenous line contiguous contamination current clinical practice often one use antibiotic treatment immediately , unless significant clinical sign symptom and/or patient status justifies intervention antibiotic . The latter tends vancomycin many S epidermidis strain resistant agent . hLF1-11 hypothesized antibacterial effect Staphylococcus epidermidis , amongst strain . Should hLF1-11 show effective antibacterial Staphylococcus epidermidis , use would justify serious hospital-acquired infection MRSA hLF1-11 show ( preclinical vitro vivo data ) display strong therapeutic effect . Choice Patient Population Based preclinical data hLF1-11 show possess antibacterial effect select bacteria ( Staphylococcus epidermidis ) . Staphylococcus epidermidis commensal find human skin . In current clinical practice hospital-acquired systemic Staphylococcal epidermidis routinely treat unless bacteremia accompany clear clinical risk patient .</detailed_description>
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Lactoferrin</mesh_term>
	<criteria>Hospitalized patient positive blood culture Staphylococcus epidermidis . Diagnosis staphylococcal infection base positive culture Staphylococcus epidermidis 2 consecutive occasion within 12 hour . Study medication must start later 24 hour last qualifying positive blood culture . Patients antibiotic treatment clinically indicate start study . Patients must sufficient venous access permit administration study drug monitoring safety variable . Patients hepatic renal parameter within 2X ULN ( upper level normality ) screening . Fecund females patient must pregnant ( confirmed pregnancy test entry ) must appropriate mechanical ( intrauterine device ) pharmacological ( `` pill '' ) contraception . Written informed consent must obtain admission study . Prior antibiotic usage : patient receive ( within 48 hour study entry ) systemic antistaphylococcal antibiotic long 24 hour . Concomitant antibiotic antibacterial agent except allow protocol lifethreatening complication . Patients device infect Staphylococcus epidermidis important pathogen , include implant , heart valves catheter . Patients known AIDS HIVpositive . Neutropenic patient neutrophil count 0.5x10^9/L . Patients staphylococcal endocarditis , mediastinitis , meningitis , osteomyelitis and/or joint infection , lung/pleural infection , septic shock . Patients methicillinsensitive coagulasenegative staphylococcus ( CNS ) infection ( MSSE ) . Patients know hypersensitivity constituent hLF111 . Patients receive investigational drug within three month prior study may interfere interpretation study result . Patients concomitant medical condition , , opinion Investigator , participation may create unacceptable risk patient . Patients consider inappropriate PI enrolment study , reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>S. epidermidis</keyword>
	<keyword>Staphylococcus</keyword>
	<keyword>Lactoferrin</keyword>
	<keyword>hLF1-11</keyword>
	<keyword>Bacteraemia</keyword>
</DOC>